SCHEMBL12197845

SCHEMBL12197845

COc1ccc(NS(=O)(=O)c2ccc(NC(=O)c3ccccn3)cc2)cc1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.80
GAA P10253 2/20 0.80
GRM4 Q14833 5/20 0.77
SMN1; SMN2 Q16637 3/20 0.76
NPC1 O15118 2/20 0.76
RAB9A P51151 2/20 0.76
PKM P14618 2/20 0.76
HTT P42858 2/20 0.65
RXFP1 Q9HBX9 1/20 0.64
LMNA P02545 2/20 0.62
TSHR P16473 1/20 0.62
AVPR2 P30518 1/20 0.61
GPR27 Q9NS67 1/20 0.61
POLB P06746 1/20 0.61
TDP1 Q9NUW8 1/20 0.60
THRB P10828 1/20 0.60
CCR9 P51686 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30926909 0.89 MAPT (1.00) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL27179438 0.89 MAPT (1.00) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL12197843 0.89 MAPT (0.74) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL12197830 0.87 GRM4 (1.00) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL3092361 0.87 SMN1; SMN2 (1.00) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL12197854 0.86 GRM4 (0.83) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL12197875 0.86 LMNA (0.68) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL8626109 0.86 CCR9 (0.66) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL12197846 0.85 GRM4 (0.85) MAPTGAAGRM4SMN1; SMN2NPC1
SCHEMBL12197842 0.84 GRM4 (0.75) GAAGRM4SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110243844-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK SHARP & DOHME CORP. 2011-10-06 US disclosed
US-20110243844-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK SHARP & DOHME CORP. 2011-10-06 US disclosed
WO-2010033350-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK & CO., INC. (US) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243844-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS GRM4, GRIA4, GRM1 MAPT 1712/4885GAA 3243/4885GRM4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.